Cited by 386Liver Disease Diagnosis and TreatmentLiver physiology and pathologyLiver Diseases and Immunity

The DOI matches its Crossref record; 135 of the 137 references it cites were found in a registry or an index.

Adaptive immunity: an emerging player in the progression of NAFLD

Open access

Sutti, Salvatore, Albano, Emanuele·2020·Nature Reviews Gastroenterology & Hepatology

DOI 10.1038/s41575-019-0210-2PMC PMC7222953

Open this paper in CoChat — free account Open PDF

Abstract

In the past decade, nonalcoholic fatty liver disease (NAFLD) has become a leading cause of chronic liver disease and cirrhosis, as well as an important risk factor for hepatocellular carcinoma (HCC). NAFLD encompasses a spectrum of liver lesions, including simple steatosis, steatohepatitis and fibrosis. Although steatosis is often harmless, the lobular inflammation that characterizes nonalcoholic steatohepatitis (NASH) is considered a driving force in the progression of NAFLD. The current view is that innate immune mechanisms represent a key element in supporting hepatic inflammation in NASH. However, increasing evidence points to the role of adaptive immunity as an additional factor promoting liver inflammation. This Review discusses data regarding the role of B cells and T cells in sustaining the progression of NASH to fibrosis and HCC, along with the findings that antigens originating from oxidative stress act as a trigger for immune responses. We also highlight the mechanisms affecting liver immune tolerance in the setting of steatohepatitis that favour lymphocyte activation. Finally, we analyse emerging evidence concerning the possible application of immune modulating treatments in NASH therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s41575-019-0210-2

Cites

135 of 135 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
Tilg, H., & Moschen, A. R. (2010) · Hepatology · doi:10.1002/hep.24001 · Cited by 2,548
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W. Z., Strowig, T., Thaiss, C. A., Kau, A. L., Eisenbarth, S. C., Jurczak, M. J., et al. (2012) · Nature · doi:10.1038/nature10809 · Cited by 2,435
Nonalcoholic Fatty Liver Disease
Rinella, M. E. (2015) · JAMA · doi:10.1001/jama.2015.5370 · Cited by 2,320
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030
Estes, C., Anstee, Q. M., Arias, M., Bantel, H., Bellentani, S., Caballería, J., Colombo, M., Craxì, A., Crespo, J., Day, C. P., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.05.036 · Cited by 2,046
Dietary and Genetic Obesity Promote Liver Inflammation and Tumorigenesis by Enhancing IL-6 and TNF Expression
Park, E. J., Lee, J. H., Yu, G.-Y., He, G., Ali, S. R., Holzer, R. G., Österreicher, C. H., Takahashi, H., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2009.12.052 · Cited by 1,764
Immunology in the liver — from homeostasis to disease
Heymann, F., & Tacke, F. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.200 · Cited by 1,180
Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites†
Neuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.23719 · Cited by 1,077
The immunology of hepatocellular carcinoma
Ringelhan, M., Pfister, D., O’Connor, T., Pikarsky, E., & Heikenwalder, M. (2018) · Nature Immunology · doi:10.1038/s41590-018-0044-z · Cited by 1,076

Show all 137 references

Sorted by citations

Items 301–386 of 386

CD4+ T cells promote fibrosis during metabolic dysfunction–associated steatohepatitis
Valenzuela-Pérez, L., Lee, H. S. K., Bayer, R. L., Manna, D. F., Mishra, S. K., Washington, A. M., Hassan, A., Sidahmed, M. M., Ssali, E., Dinç, E. J., et al. (2026) · Hepatology · doi:10.1097/hep.0000000000001772 · Cited by 4
Human hepatocyte PNPLA3 148M exacerbates rapid non-alcoholic steatohepatitis development in chimeric micePreprint
Kabbani, M., Michailidis, E., Steensels, S., Fulmer, C. G., Luna, J. M., Pen, J. L., Tardelli, M., Razooky, B. S., Ricardo-Lax, I., Zou, C., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.19.387613 · Cited by 2
The role of B cells in metabolic (dysfunction)-associated fatty liver disease
Pan, Z., Chan, W., & Eslam, M. (2021) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-21-404 · Cited by 2
Longitudinal analysis of a dietary mouse model of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)Preprint
Saenz, M., McDonough, J. C., Bloom‐Saldana, E., Irimia, J. M., Cauble, E. L., Castillo, A., Fueger, P. T., & Treviño, L. S. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.19.540989 · Cited by 2
Anti-tumor immunity relies on targeting tissue homeostasis through monocyte-driven responses rather than direct tumor cytotoxicityPreprint
Koelsch, N. J., Mirshahi, F., Aqbi, H. F., Seneshaw, M., Idowu, M. O., Olex, A. L., Sanyal, A. J., & Manjili, M. H. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.12.598563 · Cited by 2
Editorial: Inflammatory responses on the road from NASH to HCC: pathogenic mechanisms and possible therapeutic strategies
Kornek, M., Hendrikx, T., & Sutti, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1512363 · Cited by 2
Self-citation
The double-edged sword of regulatory T cells in MASLD: from inflammation control to fibrosis promotion
Lee, S. E., Jo, M. G., Park, S. W., Kim, H. J., Yun, S. P., & Kim, J.-W. (2026) · Animal Cells and Systems · doi:10.1080/19768354.2026.2630463 · Cited by 2
“Tregs consistently exhibit an increased susceptibility to apoptosis in MASH (Sutti and Albano 2020).”
New insights into NAFLD based on preclinical MRI studies
Bamburowicz‐Klimkowska, M., Ruzycka-Ayoush, M., Cieszanowski, A., Szeszkowski, W., Białek, M., Małkowska, A., & Grudziński, I. P. (2022) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2022.105192 · Cited by 1
Identification and Validation of Biomarkers in Metabolic Dysfunction‐Associated Steatohepatitis Using Machine Learning and Bioinformatics
Zhang, Y., Li, J., Zeng, H., Liu, S., Luo, Y., Yu, P., & Liu, J. (2025) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.70063 · Cited by 1
Peripheral blood lymphocyte subsets of Chinese adults with liver steatosis
Yan, X., Li, J., Wang, Q., Xu, T., & Wu, D. (2025) · Scientific Reports · doi:10.1038/s41598-025-99510-x · Cited by 1
Identification of pyroptosis-associated gene to predict fibrosis and reveal immune characterization in non-alcoholic fatty liver disease
Tu, S., Xi, J., Bu, X., Zhang, Q., Liao, S., Zhu, X., Guo, Y., & Sha, W. (2025) · Scientific Reports · doi:10.1038/s41598-025-96158-5 · Cited by 1
Gestational Melatonin Supplementation Attenuates Maternal Sleep Deprivation‐Induced Steatohepatitis Susceptibility in Offspring
Guo, F., Yang, Z., She, J., Chen, F., Hu, Y., Huang, H.-F., & Gao, L. (2025) · Cell Proliferation · doi:10.1111/cpr.70138 · Cited by 1
Dynamic immune response and its influencing factors in COVID-19 patients with non-alcoholic fatty liver disease: A cohort study
Yan, P., Li, R., Yuan, X.-Y., Wang, Y., Lan, L.-J., Yu, X.-P., & Liu, D.-F. (2026) · World Journal of Hepatology · doi:10.4254/wjh.v18.i2.113004 · Cited by 1
Neutrophil extracellular traps: A central player in liver diseases
Wang, H., Tsung, A., & Zhang, H.-J. (2026) · Hepatology Communications · doi:10.1097/hc9.0000000000000970 · Cited by 1
Prunella vulgaris polyphenols mediate the gut-liver axis to improve MASLD: regulating cholesterol metabolism and gut microbiota
Li, C., Liu, Y., Ye, S., Zhang, H., Sun, M., Liao, Y., Lin, Y., Tian, S., Luo, K., & Zhang, Z. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1838289 · Cited by 1
Thermoneutrality Accelerates a Distinctive Metabolic Dysfunction–Associated Steatohepatitis Phenotype in a Diet-Induced Male Mouse Model With Similarities to Human Disease
Leke, R., Tan, J. Y., Ling, S., Siddiqui, M., Kakol‐Palm, D., Lindblom, A., Andréasson, A., Pellegrini, G., Söderberg, M. P., Zuydam, N. V., et al. (2026) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2026.101866 · Cited by 1
Nonlinear Relationship Between Systemic Immune-Inflammation and Hepatic Steatosis: A Population-Based Study in China
Zhao, J., Yu, L., Sun, K., Wang, Y., & Xie, F. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s440430 · Cited by 1
Immune cell balance as potential biomarker of progressing non-alcoholic fatty liver disease
Topchieva, L. V., Валерьевна, К. И., Дуданова, О. П., Vasileva, A., & Жулай, Г. А. (2024) · Genes and Cells · doi:10.17816/gc610252 · Cited by 2
Multiscale 3D genome organization underlies duck fatty liver with no adipose inflammation or serious injury
Ning, M., Song, L., Niu, X., Wang, Y., Liu, W., Hu, J., Cai, H., Song, W., Liu, L., Li, H., et al. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.132452 · Cited by 2
A comparative study on the effect of melatonin and orlistat combination versus orlistat alone on high fat diet-induced hepatic changes in the adult male albino rats (a histological and morphometric study)
El-Sayed, S., El-Sayed, G. A., Mansour, M. A., Ahmed, E. H., & Kamar, S. A. (2024) · Ultrastructural Pathology · doi:10.1080/01913123.2024.2438380 · Cited by 1
Comprehension of gut microbiota and microRNAs may contribute to the development of innovative treatment tactics against metabolic disorders and psychiatric disorders
Nakashima, M. (2024) · International Journal of Physiology Pathophysiology and Pharmacology · doi:10.62347/wazh2090 · Cited by 2
Nonalcoholic Fatty Liver Disease
Kawaguchi‐Suzuki, M. (2017) · The American Pharmacists Association eBooks · doi:10.21019/pharmacotherapyfirst.nafld_overview · Cited by 1
The Potential of mecciRNA in Hepatic Stellate Cell to Regulate Progression of Nonalcoholic HepatitisPreprint
Liu, B., Tian, Y., He, J., Gu, Q., Jin, B., Hao, S., Li, W., Shi, L., Yu, H., Ge, S., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1713942/v1 · Cited by 1
Maternal Western-style Diet Promotes Immune Tolerance and Liver Sinusoidal Endothelial Cell Dysfunction in Nonhuman Primate Juvenile Offspring LiverPreprint
Nash, M. J., Nelson, B. N., McGuckin, M. M., Janssen, R. C., Jones, K. L., Al‐Juboori, S. I., Dobrinskikh, E., Kievit, P., Aagaard, K. M., McCurdy, C. E., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.06.697995 · Cited by 1
Gene expression signature of exercise and change of diet on non-alcoholic fatty liver disease in mice
Melo, L., Hagar, A., & Klaunig, J. E. (2021) · Comparative Exercise Physiology · doi:10.3920/cep210033
Nichtalkoholisch induzierte Fettleber: Wie CD8-T-Zellen das Gewebe schädigen
Dudek, M., & Knolle, P. A. (2021) · Deutsches Ärzteblatt · doi:10.3238/persimmun.2021.09.17.07
Targeted Inhibition of the Immunoproteasome Blocks Endothelial MHC Class II Antigen Presentation to CD4 + T Cells in Chronic Liver InjuryPreprint
Zhang, Y., Yang, X., Bi, T., Wu, X., Wang, L., Ren, Y., Ou, Y., Xie, C., Li, K., Ran, H., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3990739
Immune dysregulation in nonalcoholic steatohepatitis
Chatterjee, A., & Basu, P. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821232-5.00023-9
Investigation of the potential mechanism of the Shugan Xiaozhi decoction for the treatment of nonalcoholic fatty liver disease based on network pharmacology and molecular dockingPreprint
Xing, Y., Yang, R., Yang, H., Jiang, D., Xu, L., & Feng, L. (2022) · Research Square · doi:10.21203/rs.3.rs-1294807/v1
Chemotherapy for hepatocellular carcinoma—an updated review
Sarojamma, V., Shaik, J. B., Damu, A. G., & Vadde, R. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99283-1.00005-7
Nonalcoholic steatohepatitis-induced hepatocellular carcinoma
Hakami, A., & Elmakki, E. (2022) · King Khalid University Journal of Health Sciences · doi:10.4103/kkujhs.kkujhs_1_22
Modulación de la microbiota intestinal en el tratamiento de la enfermedad de hígado graso no alcohólico y síndrome metabólico. Estudio de un tratamiento experimental con quercetina y de la transferencia de microbiota a ratones libres de gérmenes = Intestinal microbiota modulation in the treatment of non-alcoholic fatty liver disease and metabolic syndrome. Study of an experimental treatment with quercetin and intestinal microbiota transfer to germ-free mice
Porras, D. (2021) · Buleria (Universidad de León) · doi:10.18002/10612/13641
Angeborene und erworbene Immunität im Kontext der nichtalkoholischen Fettlebererkrankung
Heinrich, B. (2022) · Zeitschrift für Gastroenterologie - German Journal of Gastroenterology · doi:10.1055/a-1993-3519
Angiopoietin-like 4 shapes the intrahepatic T-cell landscape via eIF2α signaling during steatohepatitis in diet-induced NAFLDPreprint
Low, Z. S., Chua, D., Cheng, H. S., Tee, R., Tan, W., Ball, C., Sahib, N. B. E., Ng, S. S., Qu, J. T., Liu, Y., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.10.523354 · Cited by 1
Bioenergetic and redox signaling in hepatic steatosis models: Integrative analysis of nutritional, hormonal, and inflammatory stimuli
Kakimoto, P. A. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.46.2021.tde-10082023-115406
Level of IL-6 and IL-8 and their associations with non-alcoholic fatty liver disease in patients with type 2 diabetes
Mykhalchyshyn, G., Kobyliak, N. M., Komisarenko, I., & Yerokhovych, V. (2023) · Ukrainian Scientific Medical Youth Journal · doi:10.32345/usmyj.3(141).2023.88-96
Additional file 4 of The potential of mecciRNA in hepatic stellate cell to regulate progression of nonalcoholic hepatitis
Liu, B., Tian, Y., He, J., Gu, Q., Jin, B., Shen, H., Li, W., Shi, L., Yu, H., Shan, G., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20921202
Additional file 7 of The potential of mecciRNA in hepatic stellate cell to regulate progression of nonalcoholic hepatitis
Liu, B., Tian, Y., He, J., Gu, Q., Jin, B., Shen, H., Li, W., Shi, L., Yu, H., Shan, G., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20921211
Additional file 8 of The potential of mecciRNA in hepatic stellate cell to regulate progression of nonalcoholic hepatitis
Liu, B., Tian, Y., He, J., Gu, Q., Jin, B., Shen, H., Li, W., Shi, L., Yu, H., Shan, G., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20921217
Additional file 6 of The potential of mecciRNA in hepatic stellate cell to regulate progression of nonalcoholic hepatitis
Liu, B., Tian, Y., He, J., Gu, Q., Jin, B., Shen, H., Li, W., Shi, L., Yu, H., Shan, G., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20921208
Additional file 5 of The potential of mecciRNA in hepatic stellate cell to regulate progression of nonalcoholic hepatitis
Liu, B., Tian, Y., He, J., Gu, Q., Jin, B., Shen, H., Li, W., Shi, L., Yu, H., Shan, G., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20921205
Immune cells and blood lipids mediation: a Mendelian randomization study on metabolic dysfunction-associated fatty liver diseasePreprint
Shen, Q., Liu, Z., Huang, H., Liang, Y., Chen, M., & Xu, C. (2024) · Research Square · doi:10.21203/rs.3.rs-4226794/v1
Do autoantigens drive MASH progression?
Valenzuela-Pérez, L., Lee, H. S. K., & Hirsova, P. (2024) · Hepatology · doi:10.1097/hep.0000000000001048
Common molecular basis for MASH and hepatitis C revealed via systems biology approach
Cheng, Y., Song, Z., Liu, Y., Xu, X., Zhang, D., Zou, Y., Liu, L., Zeng, Y., Li, W., Bai, D., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1442221
Unveiling the endocrine connections of NAFLD: evidence from a comprehensive mendelian randomization study
Li, F., Wu, M., Wang, F., Luo, L., Wu, Z., Huang, Z., & Wen, Z. (2024) · Biomedical Engineering Letters · doi:10.1007/s13534-024-00442-8
Causal associations of immunophenotypes with metabolic dysfunction-associated fatty liver disease and mediating pathways: a Mendelian randomization study
Xie, K., Chen, M., An, H., Gao, J., Tang, C., & Huang, Z. (2024) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223241303649
Immune metabolic changes identify causal candidate genes and enable diagnostic frameworks in MAFLD
Qiao, J., Wu, Y.-W., Wang, Y.-Y., Huang, J.-J., & Shan, P.-F. (2025) · Scientific Reports · doi:10.1038/s41598-025-17406-2 · Cited by 1
Integrated Multi-Omic Analysis Reveals Causal Relationships and Causal Mechanisms of Peripheral Lymphocyte-Driven Remodeling in the Intrahepatic Immune Microenvironment of Early-Stage MAFLD
Guo, S., Li, Z., Han, Z., Ge, Y., Shi, H., Zheng, Y., Tan, W., Cheng, X., Li, Z., Yao, L., et al. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s546860
Additional file 1 of Identification of necroptosis genes and characterization of immune infiltration in non-alcoholic steatohepatitis
Zhang, H., He, Y., Zhao, Y., Axinbai, M., Hu, Y., Liu, S., Kong, J., Sun, J., & Zhang, L. (2024) · Figshare · doi:10.6084/m9.figshare.27140664
Additional file 1 of The potential of mecciRNA in hepatic stellate cell to regulate progression of nonalcoholic hepatitis
Liu, B., Tian, Y., He, J., Gu, Q., Jin, B., Shen, H., Li, W., Shi, L., Yu, H., Shan, G., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20921187
Additional file 5 of Identification of necroptosis genes and characterization of immune infiltration in non-alcoholic steatohepatitis
Zhang, H., He, Y., Zhao, Y., Axinbai, M., Hu, Y., Liu, S., Kong, J., Sun, J., & Zhang, L. (2024) · Figshare · doi:10.6084/m9.figshare.27140676
Additional file 1 of Identification and immunological characterization of lipid metabolism-related molecular clusters in nonalcoholic fatty liver disease
Liu, J., Li, Y., Ma, J., Wan, X., Zhao, M., Zhang, Y., & Shang, D. (2023) · Figshare · doi:10.6084/m9.figshare.23916867
Additional file 2 of Identification of necroptosis genes and characterization of immune infiltration in non-alcoholic steatohepatitis
Zhang, H., He, Y., Zhao, Y., Axinbai, M., Hu, Y., Liu, S., Kong, J., Sun, J., & Zhang, L. (2024) · Figshare · doi:10.6084/m9.figshare.27140667
Additional file 2 of Identification and immunological characterization of lipid metabolism-related molecular clusters in nonalcoholic fatty liver disease
Liu, J., Li, Y., Ma, J., Wan, X., Zhao, M., Zhang, Y., & Shang, D. (2023) · Figshare · doi:10.6084/m9.figshare.23916873
Additional file 2 of The potential of mecciRNA in hepatic stellate cell to regulate progression of nonalcoholic hepatitis
Liu, B., Tian, Y., He, J., Gu, Q., Jin, B., Shen, H., Li, W., Shi, L., Yu, H., Shan, G., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20921193
Additional file 8 of Identification of necroptosis genes and characterization of immune infiltration in non-alcoholic steatohepatitis
Zhang, H., He, Y., Zhao, Y., Axinbai, M., Hu, Y., Liu, S., Kong, J., Sun, J., & Zhang, L. (2024) · Figshare · doi:10.6084/m9.figshare.27140685
Additional file 3 of Identification of necroptosis genes and characterization of immune infiltration in non-alcoholic steatohepatitis
Zhang, H., He, Y., Zhao, Y., Axinbai, M., Hu, Y., Liu, S., Kong, J., Sun, J., & Zhang, L. (2024) · Figshare · doi:10.6084/m9.figshare.27140670
Additional file 6 of Identification of necroptosis genes and characterization of immune infiltration in non-alcoholic steatohepatitis
Zhang, H., He, Y., Zhao, Y., Axinbai, M., Hu, Y., Liu, S., Kong, J., Sun, J., & Zhang, L. (2024) · Figshare · doi:10.6084/m9.figshare.27140679
Additional file 4 of Identification of necroptosis genes and characterization of immune infiltration in non-alcoholic steatohepatitis
Zhang, H., He, Y., Zhao, Y., Axinbai, M., Hu, Y., Liu, S., Kong, J., Sun, J., & Zhang, L. (2024) · Figshare · doi:10.6084/m9.figshare.27140673
Additional file 3 of The potential of mecciRNA in hepatic stellate cell to regulate progression of nonalcoholic hepatitis
Liu, B., Tian, Y., He, J., Gu, Q., Jin, B., Shen, H., Li, W., Shi, L., Yu, H., Shan, G., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20921199
Additional file 7 of Identification of necroptosis genes and characterization of immune infiltration in non-alcoholic steatohepatitis
Zhang, H., He, Y., Zhao, Y., Axinbai, M., Hu, Y., Liu, S., Kong, J., Sun, J., & Zhang, L. (2024) · Figshare · doi:10.6084/m9.figshare.27140682
Nonalcoholic fatty liver disease is associated with adverse medical, but not implant-related complications following total shoulder arthroplasty
Mao, E., Le, A. S., Zhu, A. R., O'Connell, E., & Srikumaran, U. (2025) · Seminars in Arthroplasty JSES · doi:10.1016/j.sart.2025.151529
L-ascorbate prevents non-alcoholic steatohepatitis-based hepatocarcinogenesis in Sod1/Prdx4 double-knockout mice
Osaki, T., Homma, T., Maeda, Y., Yamada, K.-I., Yokoyama, C., Toyokuni, S., & Fujii, J. (2025) · Scientific Reports · doi:10.1038/s41598-025-28982-8
Metabolic dysfunction-associated fatty liver disease: A key player in colorectal cancer development and progression
Fouad, Y. M., Pan, Z., Mostafa, A. M., & Eslam, M. (2026) · World Journal of Meta-Analysis · doi:10.13105/wjma.v14.i1.113789
The gut-liver axis in chronic liver diseases: An integrative immunopathological perspective bridging animal models and human evidence.
Khafaga, A., Rudayni, H., Khalifa, N. E., Alawam, A. S., Allam, A. A., Taha, A., Naiel, M., & El-Hack, M. A. A. (2026) · Tissue & Cell · doi:10.1016/j.tice.2026.103456
The association between psoriasis and nonalcoholic fatty liver disease: Mediation analysis involving inflammatory biomarkers among U.S. adults
Wang, X., Xie, C., Deng, Y., Ren, X., Li, Y., Liu, T., Hu, B., Feng, H., & Li, Y. (2026) · PLoS ONE · doi:10.1371/journal.pone.0344681
Association Between HLA Polymorphisms and Non-Alcoholic Fatty Liver Disease in Patients with Rheumatoid Arthritis: An Observational Study
Zekić, T., Katalinić, N., Blažić, F., Čizmarević, N. S., & Čubranić, A. (2026) · Diseases · doi:10.3390/diseases14030113
Integrated Machine Learning and Multi-Omics Analysis Identifies Mitophagy-Related Core Genes and Mechanisms in Non-Alcoholic Fatty Liver Disease
Yu, Y., Zhang, T., Song, C., Lin, C., Sun, Y., & Tang, H. (2026) · Journal of Inflammation Research · doi:10.2147/jir.s575586
Modèle de carcinomes hépatocellulaires murins induits par l'expression de l'antigène T SV40 : analyse du transcriptome entier du foie et des variations d'expression ARN liées à l'âge et induites par un régime « occidental »
Hobeika, C. (2022) · theses.fr (ABES) · doi:10.70675/4c247323z584fz42b6za12cze7812b01da9e
A conserved immunometabolic transcriptional programme defines MASLD progression and is maintained in hepatocellular carcinomaPreprint
Muchovu, G. T., Gebremaryam, M. A., Igiramaboko, J. F. R., Uwamahoro, H., & Isange, C. N. (2026) · Research Square · doi:10.21203/rs.3.rs-9310352/v1
The Key Role of Complement Receptor CRIg in Kupffer Cell-Mediated Liver Disease Progression
Sun, X., & Liu, Y. (2026) · Viruses · doi:10.3390/v18040473
Terpenoids in the management of MASLD: Multi-target mechanisms, therapeutic potential, and future perspectives
Huang, C., Zhang, R., Liu, C., & Hu, C. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108231
Identification of the critical immune-related drivers shared by non-alcoholic fatty liver disease and osteoporosis
Chang, F., Ge, S., Zhang, M. Y., Wu, F., Cao, F., Liu, J., Lei, M., Guo, Z., Tang, W., Chen, M., et al. (2026) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-026-06257-3
Metabolic links between metabolic dysfunction-associated steatotic liver disease and primary biliary cholangitis
Kotlyarov, S. N. (2026) · World Journal of Hepatology · doi:10.4254/wjh.118902
Precursor Lesions in Hepatocellular Carcinogenesis
Roeb, E., & Schneider, M. (2026) · Visceral Medicine · doi:10.1159/000553489
The metabolic roles of immune checkpoint molecules
Wang, Y., Wang, J., Dan, S., Zheng, J., Lu, Y., & Xia, F. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag030
The new TRR 412 Metabolic Dysfunction-Associated Steatotic Liver Disease: From Pathophysiological Mechanisms to Translation into Tailored Therapeutic Concepts (Berlin / Dresden)
Tacke, F., Detjen, K. M., Heisig, J., & Hampe, J. (2026) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2890-7253
Hepatic T-cell dysfunction in chronic liver disease and hepatocellular carcinoma: a spatial systems-immunology framework for precision immunotherapy
Udomsinprasert, W. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2708824
Perioperative gut microbial ecology: a new frontier for improving the prognosis of hepatocellular carcinoma surgery
Hu, D., Wang, Z., Xue, Y., Li, X., Li, Y., Liu, S., Gao, L., Liu, H., & Yan, H. (2026) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbag021
B cells in the progression from metabolic dysfunction-associated steatotic liver disease to hepatocellular carcinoma: immune regulation, microenvironmental crosstalk, and therapeutic implications
Bai, H., Fan, G., Deng, B., Liu, Y., Zhang, P., Cao, X., & Li, Y. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.117306
The Role of the OSM/OSMRβ Axis in Chronic Liver Disease Progression and Hepatocellular Carcinoma Development: A Focus on MASLD/MASH
Foglia, B., Nurcis, J., Signorini, M., Novo, E., Bocca, C., Cannito, S., & Parola, M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188213
Glutamine metabolism as a rheostat of CD4+ T cell pathogenic function in metabolic dysfunction-associated steatotic liver disease
Sawada, K., Oates, J. R., Kimura, M., Stankiewicz, T. E., Eom, J., Alarcon, P. C., Chung, H., Damen, M. S. M. A., Ulanowicz, C. J., Wayland, J. L., et al. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.08.018
The Gut–Liver Axis in Metabolic Dysfunction–Associated Steatotic Liver Disease and Associated Hepatocellular Carcinoma
Huai, Q., Li, X., Wang, H., & Yin, S. (2026) · American Journal Of Pathology · doi:10.1016/j.ajpath.2026.09.004
Integrated network toxicology and transcriptomics uncover that the involvement of NF-κB/NLRP3 pyroptosis axis in mediating BaP-induced hepatotoxicity and fibrosis
Wang, B., Dong, X., Li, J., Feng, X., Chen, Y., Liu, N., Fu, P., Wang, J., & Li, X. (2026) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2026.105179
From pathophysiology to therapy: dual and triple agonists as a new frontier in metabolic dysfunction-associated steatotic liver disease
Argano, C., Maggio, D., Pollicino, C., Cangialosi, V., Manno, S. B., Orlando, V., Monti, M. L., Grutta, A., Torres, A., & Corrao, S. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1784959
Source graph data for: Transcriptomics-driven metabolic pathway analysis reveals similar alterations in lipid metabolism in mouse MASH model and human.
Tsouka, S. (2024) · Figshare · doi:10.6084/m9.figshare.25134470

Authors: Sutti, S., & Albano, E.
Affiliations: Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT)
Corresponding author: Albano, Emanuele
ORCID: Sutti, Salvatore
Albano, Emanuele
Venue: Nature Reviews Gastroenterology & Hepatology
Publisher: Springer Science and Business Media LLC
Published: 2019-10-11
Volume: 17
Issue: 2
Pages: 81-92
ISSN: 1759-5045 (ISSN-L)
1759-5053
DOI: 10.1038/s41575-019-0210-2
PMC: PMC7222953
OpenAlex: W2979371456
Cited by: 374
References: 137
Citations by year: 2026: 35 · 2025: 42 · 2024: 67 · 2023: 70 · 2022: 75 · 2021: 55 · 2020: 27 · 2019: 1
FWCI: 5.94
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.springernature.com/gp/researchers/text-and-data-mining (tdm)
www.springernature.com/gp/researchers/text-and-data-mining (vor)
Locations: Nature Reviews Gastroenterology & Hepatology (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Fondazione Cariplo (2011-0470)
Ministero dell’Istruzione, dell’Università e della Ricerca (FAR 2015)
Topics: Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
Keywords: non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, adaptive immunity, B cells, T cells, liver inflammation, liver fibrosis, hepatocellular carcinoma, immune tolerance, immunomodulatory therapy, disease progression
MeSH terms: B-Lymphocytes, Carcinoma, Hepatocellular, Humans, Immune Tolerance, Immunity, Innate, Liver Cirrhosis, Liver Neoplasms, T-Lymphocytes, Oxidative Stress, Disease Progression, Natural Killer T-Cells, Adaptive Immunity, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Adaptive immunity: an emerging player in the progression of NAFLD

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks